ClinicalTrials.Veeva

Menu

Gastric Volume in Patients on GLP-1 Medications

Children's Hospital of Philadelphia (CHOP) logo

Children's Hospital of Philadelphia (CHOP)

Status

Completed

Conditions

Diabetes

Treatments

Other: None - observational

Study type

Observational

Funder types

Other

Identifiers

NCT05903482
23-021125

Details and patient eligibility

About

Evaluating gastric volume in patients on GLP-1 RA medications

Full description

Glucagon like peptide 1 (GLP-1) receptor agonist (RA) medications have in recent years been approved for use in children with type 2 diabetes mellitis (DM) and obesity. The side effects of these medications include nausea and vomiting, and in the adult literature, delayed gastric emptying has been described. Due to the likelihood of delayed enteric motility, standard nil per os (NPO) guidelines may not be sufficient to minimize the chance of aspiration of gastric contents before anesthesia and surgery in patients receiving GLP-1 RA medications.

Investigators seek to measure the gastric volume of children on GLP-1 RA medications who are appropriately NPO (greater than/equal to 8 hours for solids and greater than/equal to 1 hour for clear liquids) using standard institutional NPO guidelines. The secondary objective is to measure the gastric volume of children not on GLP-1 RA medications, but with type 2 diabetes mellitis or obesity and/or type 1 DM.

The only study intervention is the addition of a gastric ultrasound. The gastric ultrasound is a non-invasive mode of imaging using sound waves with no known safety risks. The ultrasound will be performed while the subject is awake and will take less than 5 minutes.

Enrollment

70 patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Fasting Diabetic On GLP-1 RA

Exclusion criteria

Prior surgery that affects gastric anatomy

Trial design

70 participants in 3 patient groups

Diabetic, in GLP-1 RA
Description:
non-invasive, gastric ultrasound in children who are on GLP-1 RA medications and have type 2 diabetes mellitis (DM) and/or obesity and/or type 1 DM
Treatment:
Other: None - observational
Diabetic, not on GLP-1 RA
Description:
non-invasive, gastric ultrasound in children who are not on GLP-1 RA medications and have type 2 diabetes mellitis (DM) and/or obesity and/or type 1 DM.
Treatment:
Other: None - observational
Non-diabetic, not on GLP-1 RA
Description:
non-invasive, gastric ultrasound in non-diabetic children who are not on GLP-1 RA medications and do not have diabetes or obesity.
Treatment:
Other: None - observational

Trial contacts and locations

1

Loading...

Central trial contact

Elaina Lin, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems